One of the key learning outcomes of university education in general, and liberal arts programmes,  in particular, is that ...

Shanda Group has entered a period of renewed visibility, with a series of incubated ventures coming to light over the past several months. At the center of this momentum is its founder, Tianqiao Chen, ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

For those born around the time of India’s independence, it will evoke instant memories, but in terms of the guard rails of sociopolitical ethics and the human potential to take a “position,” it has ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

In comparison, he writes, the 300,000 years since Homo sapiens evolved is so brief that “in a single stroke with a medium-grained nail file you could eradicate human history.” In this special issue on ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...